IN : Cadila Healthcare Ltd - Operationally in line; opportunities abound

4QFY21 revenue and EBITDA were in line with our estimates, while PAT was above our estimate aided by the deferred tax benefit. Lower offtake of Asacol HD and pricing pressure led to the decline in US business revenue during the quarter. We reiterate our Add rating with a higher SOP-based TP of Rs692.

Most Viewed See latest

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers